New daily pill aims to outperform standard HIV therapy in landmark trial
Disease control
Recruiting now
This study tests a new experimental drug, ACC017, taken once daily alongside two other HIV medications (FTC/TAF), in adults with HIV-1 who have never been treated before. The goal is to see if ACC017 is as safe and effective as the current standard drug dolutegravir at lowering t…
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC